Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02333045 · ClinicalTrials.gov registry record · NA
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT02333045 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 4 participants.
The verdict
NCT02333045, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV infection.
Interventions
- DRUG Truvada qd
- DRUG Maraviroc 300 qd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-10-28 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02333045
The ClinicalTrials.gov registry entry for NCT02333045 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Truvada qd is the first listed.
NCT02333045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02333045 about?
NCT02333045 is a clinical study titled "Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women". This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and antiinflammatory drug called maraviroc, a medicine used in the treatment of HIV ...
What is the current status of trial NCT02333045?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2015-01. Estimated completion is 2016-10-28.
What interventions are being tested in trial NCT02333045?
The interventions under investigation include: Truvada qd (DRUG), Maraviroc 300 qd (DRUG).
Who is sponsoring clinical trial NCT02333045?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.